Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 71

Understand HTR2A antidepressant testing, common variants, evidence for response and side effects, report limitations, and why current guidelines recommend no HTR2A-based action.

HTR2A Genetic Test: Antidepressant Response, Side Effects, and Results

Understand what an IFNL3 or IL28B genetic test shows, how CC, CT, and TT results were used in older hepatitis C care, and why modern DAA treatment relies on other clinical tests.

IFNL3 Genetic Test: Hepatitis C Treatment Response and Results

Learn how NAT2 testing identifies slow, intermediate, or rapid isoniazid acetylator status, what the result may mean for TB treatment and toxicity, and why specialist monitoring remains essential.

NAT2 Genetic Test: Isoniazid Metabolism, Slow Acetylator Status, and Results

Understand NUDT15 test results, thiopurine leukopenia risk, and how normal, intermediate, or poor metabolizer status can affect mercaptopurine, azathioprine, and thioguanine starting doses.

NUDT15 Genetic Test: Thiopurine Toxicity, Leukopenia Risk, and Results

Understand what an OPRM1 genetic test shows, how AA, AG, and GG results relate to opioid response, why dosing guidance is limited, and how to use results safely.

OPRM1 Genetic Test: Opioid Response, Pain Treatment, and Results

Learn how pain medication pharmacogenetic testing uses CYP2D6, OPRM1, and related genes to clarify opioid response, codeine and tramadol risks, test results, and treatment choices.

Pain Medication Pharmacogenetic Test: Opioids, CYP2D6, OPRM1, and Results

Understand what a pharmacogenetic panel test measures, which medication-response genes may be actionable, how results are interpreted, and how panels can guide safer prescribing.

Pharmacogenetic Panel Test: Medication Response, Gene Variants, and Results

Learn what psychiatric pharmacogenetic testing can and cannot predict for antidepressants and antipsychotics, including CYP2D6, CYP2C19, SLC6A4, results, limits, and safe treatment use.

Psychiatric Pharmacogenetic Test: Antidepressants, Antipsychotics, Genes, and Results

Learn how RYR1 genetic testing evaluates malignant hyperthermia susceptibility, what positive, negative, and uncertain results mean, and how to plan safe trigger-free anesthesia.

RYR1 Genetic Test: Malignant Hyperthermia Risk and Anesthesia Results

Understand SLC6A4 genetic testing, 5-HTTLPR and rs25531 results, the evidence on SSRI response, why guidelines do not recommend stand-alone prescribing changes, and how to use findings safely.

SLC6A4 Genetic Test: Antidepressant Response, Serotonin Transporter, and Results

Learn what an SLCO1B1 genetic test reveals about simvastatin exposure and statin muscle-risk, how results are reported, and how clinicians may use them safely.

SLCO1B1 Genetic Test: Statin Muscle Risk, Simvastatin, and Results

Understand how a statin pharmacogenetic test uses SLCO1B1, ABCG2, and CYP2C9 results to assess muscle-risk and guide safer, effective statin choices.

Statin Pharmacogenetic Test: SLCO1B1, Muscle Pain Risk, and Results

Learn how CYP3A5 pharmacogenetic testing can guide an initial tacrolimus dose after transplant, how results are interpreted, and why trough monitoring remains essential.

Tacrolimus Pharmacogenetic Test: CYP3A5, Dose, Transplant, and Results

Learn how TPMT and NUDT15 pharmacogenetic testing predicts thiopurine toxicity risk, guides safer starting doses, and works with ongoing blood-count monitoring.

Thiopurine Pharmacogenetic Test: TPMT, NUDT15, Toxicity Risk, and Results

Learn how a TPMT genetic test predicts azathioprine and mercaptopurine toxicity risk, how metabolizer results guide starting doses, and why NUDT15 and blood monitoring still matter.

TPMT Genetic Test: Thiopurine Toxicity, Azathioprine, Mercaptopurine, and Results

Learn how UGT1A1 testing can predict irinotecan toxicity risk, support a Gilbert syndrome diagnosis, and clarify the meaning of *28, *6, and metabolizer results.

UGT1A1 Genetic Test: Irinotecan Toxicity, Gilbert Syndrome, and Results

1...707172...137 Page 71 of 137